Prednisone
Prednisone 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Prostate Cancer、Prostatic Neoplasms、Peripheral T Cell Lymphoma、Angioimmunoblastic T-cell Lymphoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
8 项
已进入 III/IV 期
24 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Merck Sharp & Dohme LLC
- M.D. Anderson Cancer Center
- Alliance for Clinical Trials in Oncology
- University of Rochester
- Region MidtJylland Denmark
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
- National Cancer Institute (NCI)
- Dizal Pharmaceuticals
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
丹麦、西班牙、美国、中国、澳大利亚、加拿大、新西兰、Puerto Rico、Chile、Colombia、Mexico、瑞士
正在招募患者的 Prednisone 研究
Prednisolone Treatment in Acute Interstitial Nephritis
IV 期招募中丹麦NCT04376216Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain
不适用招募中西班牙NCT07624838Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
I 期招募中美国NCT04301076DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
I 期 / II 期招募中中国NCT07059650Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
III 期招募中美国澳大利亚加拿大新西兰NCT03959085Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
III 期招募中美国ChileColombiaMexicoNCT03678025RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL
II 期招募中中国NCT06674096Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial
II 期招募中美国NCT06841705A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
III 期招募中美国澳大利亚Brazil加拿大NCT06136650A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
II 期招募中美国Brazil加拿大法国NCT05039619Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
I 期 / II 期招募中中国NCT06760039A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
不适用招募中中国NCT05899621Baricitinib in Patients With Relapsing or naïve Dermatomyositis
III 期招募中法国NCT04972760Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
I 期 / II 期招募中中国NCT06829771Mycophenolate Mofetil w/ Prednisone for Immune Related Hepatitis From Checkpoint Inhibitor Therapy
II 期招募中美国NCT07663422Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF
III 期招募中法国NCT04702256Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement
I 期 / II 期招募中中国NCT04432714A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
I 期 / II 期招募中美国NCT06457919Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
II 期招募中美国NCT06649812Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia
I 期招募中美国NCT05302271Infliximab for Immune Checkpoint Inhibitor Associated AKI
IV 期招募中美国NCT07683975Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
II 期招募中美国NCT04734730Interscalene vs Phrenic-sparing Blocks in Obesity and Effect of Maximum Inspiratory Pressure
不适用招募中美国NCT07216820Comparative Effectiveness of Upadacitinib vs Corticosteroids as First-Line Therapy for Acute Severe Ulcerative Colitis（UPFRONT）
IV 期招募中中国NCT07546097
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。